copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus This real-world, comparative cohort study aims to evaluate the 12-month effectiveness of oral versus subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2D), with a specific focus on sex-based differences in metabolic response A total of 212 patients were enrolled and evenly assigned to either oral or subcutaneous semaglutide The primary outcome was the change in HbA1c
230-OR: Comparative Effectiveness of Semaglutide in Type 2 Diabetes . . . The objective of this study was to generate real-world evidence to support clinical decision-making by evaluating the long-term effects of once-weekly SC semaglutide (sema) in routine clinical practice SEPRA was a 2-year open-label, randomized, pragmatic study (NCT03596450) comparing the effectiveness of sema vs physician’s choice standard of care (SOC; any antidiabetes drug excluding sema
Effectiveness of semaglutide on survival outcomes in patients with type . . . Background Type 2 diabetes (T2D) and chronic kidney disease (CKD) significantly increase the risk of cardiovascular events, including death and heart failure (HF) The FLOW trial demonstrated that semaglutide reduces all-cause death, cardiovascular events and HF risk in patients with T2D and CKD Since there is a difference in patient characteristics between clinical trials and real-world data
Better Limb Protection With Semaglutide vs Common T2D Meds Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a markedly lower risk for major limb events than the use of other glucose
Study Finds Oral Semaglutide Vastly Reduces Heart Attacks, Strokes A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug significantly reduces cardiovascular events in people with type 2 diabetes, pre-existing cardiovascular disease, and or chronic kidney disease
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in . . . Abstract Introduction: In this phase 4, multicentre, prospective, non-interventional PIONEER REAL Netherlands study, we assessed clinical outcomes associated with once-daily oral semaglutide use in real-world clinical practice in adults living with type 2 diabetes (T2D) naïve to injectable glucose-lowering medication